% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • camptownn camptownn Apr 23, 2013 8:11 AM Flag

    Institutional Selling - Ingalls and Snyder

    Ingalls and Snyder sold 1.3M in 1st Qtr.

    INGALLS & SNYDER LLC 03/31/2013 418,311 (1,249,200) (74.91) 1,569

    Long time investor if I am not mistaken.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Well all the big boys upped their ownership in Q1 - Not a bad sign Fidelity increased 20%, Ariel increased 71%

      Owner Name Date Shared Held Change Change(%) Value

      FEDERATED INVESTORS INC /PA/ 03/31/2013 7,585,576 2,308,402 43.74 27,232
      FMR LLC 03/31/2013 7,253,195 1,206,288 19.95 26,039
      PRICE T ROWE ASSOCIATES INC 03/31/2013 4,718,400 (24,900) (0.53) 16,939
      BLACKROCK FUND ADVISORS 03/31/2013 2,705,471 238,670 9.68 9,713
      ARIEL INVESTMENTS, LLC 03/31/2013 2,656,967 1,108,610 71.60 ,539
      BARCLAYS GLOBAL INVESTORS U 03/31/2013 2,136,250 (2,358) (0.11) 7,669
      VANGUARD GROUP INC 03/31/2013 2,094,321 97,706 4.89 7,519

      Read more:

    • As long as Mr. Singer did not sell, fine with me..

    • Federated added 2.3 M shares in Q1. It is nice to see this long time investor adding back the shares they sold earlier last year. They moved ahead of FMR as second largest shareholder. Institutional ownership actually is creeping back up.That is the most bullish news I've seen in a while.

      When looking at the chart...VICL sits on support at 3.60 and the 200 day EMA, Williams % is very oversold and Parabolic SAR is ready to reverse directions.

      Let's see what happens today

      • 2 Replies to camptownn
      • Parabolic SAR reversed direction today. We should continue to drift up.

      • When (not if) VICL becomes a $1billion market cap company, institutions will own at least 3/4 of the shares, so seeing uptick, as small as it may be, is a positive. Let's all remember that VICL expected a longer runway to Allovectin data lock over a year ago. Why? VICL increased the float in January, 2012 allowing more shares for individuals like Mr. Singer and institutions to buy in below $4. VICL is trading today at about the level it did in Q1 2012 when the float shares were bought/absorbed. No blockbuster news in 14 months on their two drug franchises -- cancer and CMV. But Vaxfectin has attracted big pharma interest with no financial terms disclosed, IMO since it's about "proof of efficacy" in R&D at this point for big pharma who may want a piece of VICL IP.

        Paint is still drying......with the official end of trial data for Allovectin shown as August, 2013 on the FDA web site.

        Sentiment: Hold

3.12+0.01(+0.32%)Sep 28 4:00 PMEDT